The Uromigos

Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer 22.10.2024 25:43 ↓

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

Episode 360: The SUNRISE Program in Bladder Cancer 15.10.2024 46:19 ↓

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

Episode 359: #UromigosLive24 - IO after IO in RCC 09.10.2024 40:41 ↓

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville 30.09.2024 21:59 ↓

En este podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia en neadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.

Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer 30.09.2024 1:03:10 ↓

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC 28.09.2024 26:22 ↓

Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI

Episode 355: #UromigosLive24 - Radioligands in prostate cancer 28.09.2024 54:23 ↓

The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3

Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer 28.09.2024 44:00 ↓

Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio

Episode 353: #UromigosLive24 ADC session 28.09.2024 53:28 ↓

Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer

Episode 352: ESMO 2024 - RCC and Bladder review 23.09.2024 26:25 ↓

Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.

Episode 351: ESMO 2024 review part 1: prostate cancer 21.09.2024 18:48 ↓

Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....

Episode 350: ESMO 2024 - NIAGARA 16.09.2024 23:51 ↓

Fresh of the Presidential session address, Tom discusses his data with Petros commenting.

Episode 348: ESMO 2024 - UpFrontPSMA 15.09.2024 33:52 ↓

Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC

Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer 15.09.2024 17:59 ↓

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC 14.09.2024 25:47 ↓

Silke Gillessen joins us to discuss her Presidential session from ESMO 2024

Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC 14.09.2024 31:10 ↓

Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC

Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC 14.09.2024 22:32 ↓

Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC

Episode 343: ESMO 2024 - TiNivo-2 Trial 14.09.2024 31:23 ↓

Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.

Episode 342: ESMO 2024 Preview with Silke Gillessen 03.09.2024 32:24 ↓

Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024

Episode 341: Hormone Resistance in Prostate Cancer 27.08.2024 33:05 ↓

Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer

Episode 340: Cancer Immunity Cycle Update 19.08.2024 41:50 ↓

Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.

Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU 09.08.2024 18:37 ↓

María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.

Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More 06.08.2024 25:39 ↓

Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics

Episode 337: Updated NCCN Guidelines in RCC 30.07.2024 42:38 ↓

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC

Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 24.07.2024 35:35 ↓

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.